RxDoctor Payments Data

Susan Stewart

Medical · Wailuku, HINPI 1194728139

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $34,508 of the $47,111 with a category attached, or 73.2%. Gilead accounts for 99.3% of it on its own, with 3 other manufacturers making up the rest. 2025 is the largest year on record at $17,709, 6.8 times the $2,621 reported in 2021. Among medical clinicians in HI with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$47,111in general payments, 2019–2025

Across 118 payments — averaging $399.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$47K
  • Insmed, Inc.$168
  • Viiv Healthcare Company$125
  • AbbVie$34

What the payments were for

  • Consulting fees$1,9004%
  • Speaking & faculty fees$34,50873%
  • Travel & lodging$8,20717%
  • Food & beverage$2,4805%
  • Education$160%

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead112$46,784
Insmed, Inc.3$168
Viiv Healthcare Company1$125
AbbVie2$34

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$47,111 in reported general payments places this provider in the 95th percentile of 63 medical providers in Hawaii.

See all medical providers in Hawaii

Medicare billing

Part B allowed, 2024
$65,117
Medicare patients
197
Services billed
664

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala13$52,451
EliquisApixaban24$11,808
Divalproex Sodium ErDivalproex Sodium11$2,057
Famotidine23$828
Atorvastatin Calcium44$564
Oxybutynin Chloride11$525
Gabapentin20$394
Levofloxacin11$354
Olanzapine11$319
Levothyroxine Sodium19$299
Pantoprazole Sodium32$273
Tamsulosin Hcl26$265
Trazodone Hcl17$256
Amlodipine Besylate16$200
Cephalexin15$184

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy$46,784$52,45113 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 63 medical providers in Hawaii.

Other medical in Wailuku

See the full list for Hawaii

Where these figures come from

Is this you, or does something look wrong? →